{"id":"NCT02325791","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-21","primaryCompletion":"2017-07-05","completion":"2017-09-26","firstPosted":"2014-12-25","resultsPosted":"2018-11-06","lastUpdate":"2018-11-06"},"enrollment":1177,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Respiratory Syncytial Virus Infections"],"interventions":[{"type":"DRUG","name":"Suptavumab 30 mg/kg","otherNames":["REGN2222"]},{"type":"DRUG","name":"Placebo Matched to Suptavumab","otherNames":[]},{"type":"DRUG","name":"Suptavumab 30 mg/kg- 1 Dose","otherNames":[]},{"type":"DRUG","name":"Suptavumab 30 mg/kg - 2 Doses","otherNames":[]}],"arms":[{"label":"Part A: Suptavumab 30 mg/kg","type":"EXPERIMENTAL"},{"label":"Part B: Placebo Matched to Suptavumab","type":"EXPERIMENTAL"},{"label":"Part B: Suptavumab 30 mg/kg- 1 Dose","type":"EXPERIMENTAL"},{"label":"Part B: Suptavumab 30 mg/kg - 2 Doses","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of suptavumab (REGN2222) in infants born no more than 35 weeks, 6 days gestational age who are no more than 6 months of age at the time of enrollment in their respective geographic location. In order to optimize the potential benefit in this vulnerable population, we conducted this study during the RSV season using dosing regimens that are expected to be effective.","primaryOutcome":{"measure":"Part A: Serum Concentration of Suptavumab Over Time","timeFrame":"Day 1 through Day 150","effectByArm":[{"arm":"Part A: Suptavumab 30 mg/kg - 1 Dose","deltaMin":280,"sd":92.9}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":205,"countries":["United States","Australia","Bulgaria","Canada","Chile","Denmark","Finland","Germany","Hungary","Netherlands","New Zealand","Panama","Puerto Rico","South Africa","Spain","Sweden","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["32897368"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Otitis media","Pyrexia","Gastrooesophageal reflux disease"]}}